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Abstract Case Report Laboratory Values and Imaging
Cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy, or CADASIL, is a genetic disease that results in
early-onset strokes and dementia. It is one of the most common
hereditary causes of strokes and vascular dementia. The mutation
involves the NOTCH3 gene, a gene implicated in small vessel
proliferation and remodeling. Interestingly, the majority of the small
vessel pathology occurs in the vasculature of the subcortical regions of
the brain. This is a case of a female with a typical presentation of the
disease, presenting with late stage subcortical dementia. Collaborative
history from her children revealed a characteristic progression of the
disease. The study of her case will help illustrate the distinctive
manifestations of the condition often associated with the condition.
Information regarding the natural history, diagnosis, and management
will also be discussed. CADASIL is assumed to be massively under-
diagnosed, and is believed to underlie a much larger proportion of
stroke and dementia cases than previously thought.
A 54 year old Syrian female presented with several years of progressive
cognitive decline, starting with social isolation (4 years), followed by
irritability and emotional lability, with episodes of laughing or crying (3
years), began to develop inappropriate social behavior (2.5 years), loss of
urinary continence and gait disturbance and falls (2 years), apathy (1.5 year),
dysarthria (1 year), finally progressing to total memory loss and disorientation.
Prior to the start of her mental deterioration, past medical history included
chronic migraines of moderate frequency and occasional episodes of syncope.
She was not on any medication at the time but was placed on imipramine and
memantine previously for management of her progressive mental illness. Her
family history revealed that her father began suffering from very similar
symptoms in his fifth decade and died after 3 years. She did not smoke or
drink.
On observation and neuropsychiatric inventory, patient was alert but not
oriented to person, place, time, or situation. She was restless and extremely
irritable. She was mute and avoided eye contact. She was ambulatory but
appeared to have a stomping, or sensory, gait. She would sometimes speak to
herself or to people not present in the room, indicating that she was
hallucinating. Her affect was completely flat. Motor abnormalities included
peri-oral dyskinesia and twitching. She had severe psychomotor retardation.
The patient could not complete the mini mental state examination (MMSE),
short-term memory function (SMFT), or Benton tests because she was
completely disoriented. Differential diagnosis included subcortical vascular
dementia and normal pressure hydrocephalus due to her early urinary
incontinence and gait disturbance, and Lewy body dementia due to her
hallucinations and falls.
Diagnosis of subcortical vascular dementia was made based on clinical and
radiological findings. A very high likelihood of CADASIL was hypothesized
based on characteristic historical findings: early onset, migraines, syncope
(likely to be transient ischemic attacks, or TIAs), and positive family history.
Genetic testing was not performed and hence a definitive diagnosis of
CADASIL was not made.
Laboratory investigations of hematological, hepatic, renal, endocrine,
and urological panels showed decreased serum B12 (99pg/ml, RR 211-
911), which was treated with a B12 injection. Imaging could not be
completed initially due to the patient’s irritability.
Head magnetic resonance imaging (MRI) showed prominent basal
cisterns and cortical sulci, with dilated ventricles consistent with
involutional brain changes. MRI also showed bilateral symmetrical
diffuse periventricular and centrum semi-ovale hyperintensities on
T2/FLAIR, consistent with microvascular ischemic changes.
Computerized tomography (CT) showed diffuse ventricular dilation in
conjunction with widened basal cisterns, sylvian fissures, and cortical
sulci, denoting involutional brain changes. CT also showed bilateral
periventricular deep white matter hypodensities, predominantly in the
anterior region, consistent with subacute atherosclerotic
encephalopathy.
Introduction
Management and Conclusion
CADASIL (cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy) is a rare autosomal dominant disease
characterized by small vessel angiopathy that leads to early-onset strokes
and vascular dementia. It is caused by a mutation to the NOTCH3 gene
on chromosome 19[1], a gene involved in vascular smooth muscle
proliferation and remodeling. The disease was first described and
genetically mapped by Tournier-Lasserve et al in 1993[2].
A very rare and invariably fatal disease, CADASIL is estimated to affect
2/100,000 adults based on several epidemiological studies, including one
performed in Scotland (with similar rates all around the world), although
it is thought to be widely underdiagnosed [3]. CADASIL
characteristically manifests with cerebral ischemic episodes, cognitive
deficits, migraine with aura, and psychiatric disturbance [4].
Discussion
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CADASIL is an autosomal dominant small vessel vasculopathy affecting
the small arteries of the brain [1]. A related clinical entity, subcortical
vascular dementa (Binswanger’s disease) is the sporadic type and
presents with very similar dementia symptoms. CADASIL is the first
detected hereditary syndrome of vascular dementia, and is one of the
most common hereditary causes of stroke. The disease usually presents
in early adulthood, at around 30-60 years of age . It is caused by a
NOTCH3 gene mutation on chromosome 19 [5].
Figure 1.  MRI findings associated with CADASIL. First slide shows anterior 
temporal leukoencephalopathy. Second arrow shows the diffuse periventricular white 
matter lesions
Following initial diagnosis of CADASIL, it is recommended patients
undergo neurologic evaluation, psychometric studies (focusing on
executive function), brain imaging (MRI T2 FLAIR), and genetic
counseling. Psychiatric evaluation should also be performed if patients
exhibit symptoms of psychiatric illness. Since this patient presented at
such a late stage of the disease, no further investigations would have
been useful. Genetic testing of the patient and her children may have
been worthwhile but was not performed.
There is currently no treatment of proven efficacy for CADASIL.
Prophylactic therapies, such as low dose aspirin, have been proposed
for secondary prevention of ischemia and infarction; however, no
prophylactic treatment has been proven to positively alter the course of
the disease. Most treatment options are symptomatic, aiming to
improve patients’ quality of life.
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